Bokslutskommuniké for Cline Scientific AB (publ), 556867-8238, for the period 1 January – 31 December 2022

Cline Scientific AB (publ) ("Cline" or the "Company") issues the following bokslutskommuniké for 2022.

July - December 2022

• Net sales amounted to 0 (0) SEK.
• Operating profit amounted to 237,140 (-143,519) SEK
• Profit per average number of shares after tax amounted to 0.01 (-0.01)

January - December 2022

• Net sales amounted to 0 (3,991) SEK.
• Operating profit amounted to -2,317,061 (-3,503,694) SEK
• Profit per average number of shares after tax amounted to -0.15 (-0.24)

The report is published at www.clinescientific.com/financial-reports

 The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above, at 8.30am CET on 17 February 2023.

For more information, please contact:

Patrik Sundh, CEO

Email: patrik.sundh@clinescientific.com

Phone: +46 703-585 088

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55
Argongatan 2 C                                                                   Email: info@clinescientific.com
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.